General
Moderna to ask US and European regulators to allow emergency use of COVID-19 vaccine
Pharmaceutical company Moderna Inc. has said it will ask US and European regulators to allow emergency use of its COVID-19 vaccine, so that it can be widely distributed.
Key points:
- Results from a late-stage study show the vaccine was 94.1 per cent effective with no serious safety concerns
- Moderna said the shot was consistently effective across age, race, ethnicity and gender demographics
- US Food and Drug Administration advisers are scheduled to meet on December 17 to review the trial data
The company said full late-stage study results had confirmed the shots offered strong protection, and that its vaccine was 94.1 per cent effective, with no serious safety concerns.
It also reported a 100 per cent success rate in preventing severe cases.
-
General13 hours agoShark attack at Tathra Beach leaves 9yo surfer’s board in pieces
-
Noosa News14 hours agoUnborn baby boy fighting for life after 38-week pregnant woman and partner hit by racing P-platers on the Gold Coast
-
General20 hours agoCoroner recommends prison communication review after Lathan Brown’s death
-
Noosa News21 hours agoWhistleblowers claim children told to stay quiet about death of teen in Queensland residential care home